Aflac (NYSE:AFL – Get Free Report) released its quarterly earnings results on Wednesday. The financial services provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.12), Zacks reports. Aflac had a net margin of 23.55% and a return on equity of 14.97%. The company had revenue of $4.87 billion during the quarter, compared to analyst estimates of $4.45 billion. During the same period in the prior year, the business posted $1.57 EPS. Aflac’s revenue was down 9.6% compared to the same quarter last year.
Here are the key takeaways from Aflac’s conference call:
- Adjusted EPS rose 0.6% year-over-year (ex-FX) to $1.57, adjusted book value per share increased 0.5%, and adjusted ROE was 11.7% (14.5% ex-FX), which management characterized as a solid quarterly performance.
- Aflac Japan showed underlying earned premiums down ~1.2% in Q4 and management expects a further 1–2% decline in 2026, with higher expense ratios from sales promotion and product-related lapse activity.
- U.S. net earned premiums grew 4% and persistency remained strong at 79.2%, but benefit ratios widened to 48.6% and the company is intentionally increasing expenses to scale growth businesses, guiding to a 17–20% pre-tax margin for 2026.
- Strong capital and liquidity actions — creation of $2 billion in off-balance-sheet PCAP capacity, holding-company unencumbered liquidity of $4.1 billion, adjusted leverage at 21.4% within target, plus $800 million in share repurchases and $303 million in dividends in Q4.
Aflac Price Performance
Shares of AFL opened at $113.50 on Thursday. The firm has a 50-day simple moving average of $109.84 and a 200-day simple moving average of $108.48. Aflac has a fifty-two week low of $96.95 and a fifty-two week high of $115.83. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.11 and a current ratio of 0.11. The company has a market capitalization of $59.49 billion, a price-to-earnings ratio of 14.82, a price-to-earnings-growth ratio of 3.32 and a beta of 0.67.
Aflac Increases Dividend
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Wells Fargo & Company lifted their price target on shares of Aflac from $107.00 to $109.00 and gave the company an “equal weight” rating in a research report on Friday, November 7th. Morgan Stanley set a $120.00 target price on Aflac in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “buy (b+)” rating on shares of Aflac in a research note on Monday, December 22nd. Raymond James Financial reiterated an “outperform” rating and set a $119.00 price target (up from $110.00) on shares of Aflac in a report on Tuesday, December 30th. Finally, Keefe, Bruyette & Woods boosted their price objective on shares of Aflac from $108.00 to $110.00 and gave the company a “market perform” rating in a report on Thursday, October 9th. Three equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Aflac presently has an average rating of “Hold” and a consensus price target of $110.64.
Get Our Latest Stock Analysis on AFL
Aflac News Summary
Here are the key news stories impacting Aflac this week:
- Positive Sentiment: Revenue beat and strong top-line growth cited across reports — underlying revenues of ~$4.87B topped analyst estimates, supporting the upbeat revenue narrative. Aflac Delivers Strong Revenue Gains
- Positive Sentiment: Company reported fourth-quarter net earnings of $1.4B and reiterated a 5.2% increase in its first-quarter dividend, which is shareholder-friendly and likely supporting the rally. Aflac Fourth Quarter Results & Dividend
- Positive Sentiment: Revenue beat was reiterated in several earnings summaries, giving investors confidence in sales momentum despite EPS weakness. QuiverQuant: Q4 Results
- Neutral Sentiment: Analysts and press are focused on whether Japan’s improved margins are sustainable — this is a key driver for near-term earnings expectations but remains uncertain. Can Japan’s improved margins hold?
- Neutral Sentiment: PR activity and CSR programs (Aflac’s “Check for Cancer” employer campaign) provide reputational/brand support but have limited immediate earnings impact. Aflac’s Check for Cancer Campaign
- Neutral Sentiment: Management presentation scheduled at the UBS Financial Services Conference — useful for incremental guidance or tone but not a catalyst by itself. UBS Conference Participation
- Neutral Sentiment: QuiverQuant flags mixed institutional flows (some big funds adding while others trimmed) and recent insider selling activity — watch ownership shifts but interpret with caution. QuiverQuant: Institutional & Insider Activity
- Neutral Sentiment: Market attention/option activity spiked ahead of earnings, suggesting elevated short-term volatility and hedging flows. Options Trader Interest
- Negative Sentiment: EPS missed consensus: Aflac reported $1.57 EPS vs. estimates around $1.71–$1.72, and several headlines flagged the earnings shortfall — a clear near-term negative for sentiment. Zacks: Lags Q4 Earnings Estimates
- Negative Sentiment: Multiple outlets describe the quarter as “mixed” and note the bottom-line miss prompted negative price reaction in some trading — watch guidance and reserve/margin commentary next. Mixed Q4 Results — Shares Edge Lower
- Negative Sentiment: Japan net earned premiums slipped year-over-year, highlighting product/premium mix challenges in Aflac’s largest market and adding pressure to near-term profit growth. Japan Net Earned Premiums Slip
- Neutral Sentiment: Pre-earnings previews and “what to expect” coverage amplified attention but added little new info beyond the published results. Earnings Preview
Insider Buying and Selling at Aflac
In other news, EVP Steven Kent Beaver sold 5,492 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $109.53, for a total transaction of $601,538.76. Following the transaction, the executive vice president directly owned 38,368 shares of the company’s stock, valued at $4,202,447.04. This represents a 12.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Audrey B. Tillman sold 15,862 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $112.00, for a total value of $1,776,544.00. Following the completion of the transaction, the executive vice president directly owned 230,688 shares of the company’s stock, valued at $25,837,056. The trade was a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 30,044 shares of company stock valued at $3,355,981. 0.90% of the stock is owned by company insiders.
Institutional Trading of Aflac
Several institutional investors and hedge funds have recently made changes to their positions in AFL. Brighton Jones LLC lifted its holdings in shares of Aflac by 64.4% during the 4th quarter. Brighton Jones LLC now owns 14,570 shares of the financial services provider’s stock valued at $1,507,000 after buying an additional 5,708 shares during the last quarter. Bison Wealth LLC raised its position in shares of Aflac by 4.3% in the fourth quarter. Bison Wealth LLC now owns 4,402 shares of the financial services provider’s stock valued at $455,000 after purchasing an additional 183 shares during the period. Snowden Capital Advisors LLC raised its holdings in Aflac by 4.5% in the 2nd quarter. Snowden Capital Advisors LLC now owns 5,693 shares of the financial services provider’s stock worth $600,000 after acquiring an additional 246 shares during the period. Curi Capital LLC bought a new position in shares of Aflac in the second quarter worth about $276,000. Finally, WINTON GROUP Ltd bought a new position in Aflac in the 2nd quarter worth approximately $280,000. 67.44% of the stock is currently owned by hedge funds and other institutional investors.
About Aflac
Aflac Incorporated (American Family Life Assurance Company of Columbus) is a provider of supplemental insurance products designed to help policyholders manage out-of-pocket health care and living expenses. The company underwrites a range of individual and group policies that typically pay cash benefits directly to insureds when covered events occur, enabling greater financial flexibility for medical treatment, hospital stays, critical illness, and related costs. Aflac’s product mix includes supplemental health insurance, life insurance and other specialty coverages intended to complement primary medical plans.
Founded in the mid-20th century and headquartered in Columbus, Georgia, Aflac distributes its products through a combination of employer-sponsored programs, independent brokers and agents, and direct marketing.
See Also
- Five stocks we like better than Aflac
- The day the gold market broke
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Trump Planning to Use Public Law 63-43: Prepare Now
- Forget AI, This Will Be the Next Big Tech Breakthrough
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.
